Table 1 Phase 3 or 4 clinical trials based on synthetic lethal and synergistic effects from genetic-interaction screen approachesa
From: Mapping genetic interactions in cancer: a road to rational combination therapies
Genetic interaction | ClinicalTrials.gov reference | Tumor | Results available |
|---|---|---|---|
Synthetic lethality between PARP inhibition and BRCA1/BRCA2 | NCT01945775 | Breast | Yes |
NCT03150576 | Breast | No | |
NCT02163694 | Breast | No | |
NCT02184195 | Pancreatic | No | |
NCT01874353 | Ovarian | Yes | |
NCT02855944 | Ovarian | No | |
NCT01905592 | Breast | No | |
NCT02975934 | Prostate | No | |
NCT01844986 | Ovarian | Yes | |
NCT01847274 | Ovarian | Yes | |
NCT03863860 | Ovarian | No | |
NCT02000622 | Breast | Yes | |
NCT02502266 | Ovarian | No | |
Synergy between BRAF inhibition and MEK inhibitionb | NCT01584648 | Melanoma | Yes |
NCT01682083 | Melanoma | Yes | |
NCT01245062 | Melanoma | Yes | |
NCT01597908 | Melanoma | Yes | |
NCT01909453 | Melanoma | No | |
NCT02967692 | Melanoma | No | |
NCT03551626 | Melanoma | No | |
NCT01689519 | Melanoma | Yes | |
NCT03273153 | Melanoma | No | |
NCT03340506 | Melanoma, lung, glioma | No | |
Synergy between EGFR inhibition and BRAF inhibitionb | NCT02928224 | Colorectal | No |